Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Low-responders After Bariatric Surgery
NCT04643301Withdrawn
- Sponsor
- Zuyderland
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Peptides
01
Overview
Open-label trial of liraglutide in obesity, sponsored by Zuyderland. Primary endpoint: Percentage Total Weight Loss at 6 months. Planned start Dec 2020; status: withdrawn.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04643301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643301.